Page 955«..1020..954955956957..960970..»

Vascular Sealant Market to Record rise in Demand Owing to Increasing End-use Adoption 2017 2025 – Lake Shore Gazette

Posted: Published on March 20th, 2020

The global market for vascular sealants and surgical sealants has evolved rapidly in past 15 years. As cardiac surgery involves major procedures frequently with multiple suture lines, is subject to bleeding complications Continue reading

Posted in Cardiac Surgery | Comments Off on Vascular Sealant Market to Record rise in Demand Owing to Increasing End-use Adoption 2017 2025 – Lake Shore Gazette

8 High-Conviction Stocks to Buy on the Market Dip – Yahoo Finance Australia

Posted: Published on March 20th, 2020

A shopping list for the dip If there's one thing lacking in the stock market these days, it's conviction. Long-term investors are likely looking for stocks to buy to take advantage of the market weakness, but they may not know which stocks are safe to start buying and which ones could still be headed much lower. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on 8 High-Conviction Stocks to Buy on the Market Dip – Yahoo Finance Australia

Duchenne Muscular Dystrophy Treatment Market Booming by Size, Revenue and Top Growing Companies BioMarin Pharmaceuticals Incorporated, Pfizer…

Posted: Published on March 20th, 2020

Pharmacia & Upjohn LLC The report offers an in-depth assessment of key market dynamics, the competitive landscape, segments, and regions in order to help readers to become better familiar with the Duchenne Muscular Dystrophy Treatment market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to plan effective strategies for gaining successful in the Duchenne Muscular Dystrophy Treatment market. Importantly, it allows players to gain deep insights into the business development and market growth of leading companies operating in the Duchenne Muscular Dystrophy Treatment market. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Duchenne Muscular Dystrophy Treatment Market Booming by Size, Revenue and Top Growing Companies BioMarin Pharmaceuticals Incorporated, Pfizer…

Are you a Purple Heart recipient? – Sumter Item

Posted: Published on March 20th, 2020

EDITOR'S NOTE: Due to the COVID-19 pandemic, some events/meetings may be canceled or rescheduled unexpectedly. The Purple Heart Chapter of Sumter is sponsoring a project to have all Purple Heart medal recipients inducted into the National Purple Heart Hall of Honor located in New York. An enrollment application must be completed by the medal recipient or next of kin if the veteran is deceased Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Are you a Purple Heart recipient? – Sumter Item

[Up-and-coming medical startups of 2020] CES 2020 award-winning startup Exosystems unveils ‘exoRehab’ – Korea Biomedical Review

Posted: Published on March 20th, 2020

Exosystems is a startup specializing in developing healthcare wearables and digital therapeutics, providing a new platform for a healthy life in this era of population aging. The company participated in Consumer Electronics Show (CES) 2020 with its wearable exoRehab, which provides rehabilitation training for people who have difficulty in walking due to muscular dystrophy from aging and the aftereffects of a stroke. Exosystems received two CES Innovation Awards Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on [Up-and-coming medical startups of 2020] CES 2020 award-winning startup Exosystems unveils ‘exoRehab’ – Korea Biomedical Review

Thinking out loud: IP strategies for gene therapy inventions – Med-Tech Innovation

Posted: Published on March 20th, 2020

by Fiona Kellas, Reuben Jacob 16 March 2020 14:20 Reuben Jacob and Fiona Kellas, Maucher Jenkins share their expertise on IP strategies and considerations for gene therapy inventions. Gene therapy enables the treatment of a disorder or disease through the insertion of a gene into a patients cells instead of using drugs or surgery.This technique involves the introduction of genetic material into cells to compensate for abnormal genes in the patient or to make protein that will be beneficial to the patient.As an example, if a mutated gene causes a protein that is necessary for the correct functioning of cells to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein.Gene therapy is understood to be useful in the treatment of a range of conditions such as cancer, cystic fibrosis, muscular dystrophy and Alzheimers disease. UK role in gene therapy techR&D Gene therapy is considered to be very important to the future of medicine and as such, many companies are focussing their research and development into gene therapy technologies.The UK is a growing industry for research into these areas and it is anticipated that by 2035 the UK industry around cell and gene therapy technologies will be worth in the region of 10 billion.Gene therapy research is still at an early stage.Due to this length of time and the associated costs involved in developing an effective gene therapy and taking it through to approval, it will be important for companies working in this area to put into place an effective IP strategy that will provide protection for their inventions and assist them in maintaining their market position.In addition, the competitive nature of the gene therapy industry means that will be important for a company to obtain patent protection for inventions being developed, as well as reviewing the patent landscape to check that the company is free to operate in their chosen area. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Thinking out loud: IP strategies for gene therapy inventions – Med-Tech Innovation

ImStem Biotechnology Announces FDA has Lifted the Clinical Hold on the Investigational New Drug Application for IMS001 for the Treatment of Multiple…

Posted: Published on March 20th, 2020

FARMINGTON, Conn., March 20, 2020 /PRNewswire/ --ImStem Biotechnology, Inc. (Farmington CT), a biopharmaceutical company pioneering the development of human embryonic stem cell (ESC) derived mesenchymal stem cells (hES-MSC), through a proprietary method using a trophoblast intermediate stage (hence also known as T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases, today announced that the U.S Continue reading

Posted in MS Treatment | Comments Off on ImStem Biotechnology Announces FDA has Lifted the Clinical Hold on the Investigational New Drug Application for IMS001 for the Treatment of Multiple…

Coronavirus Treatment: Hundreds of Scientists Scramble to Find One – The New York Times

Posted: Published on March 20th, 2020

In an ambitious international collaboration, researchers have mapped proteins in the coronavirus and identified 50 drugs to test against it. Working at a breakneck pace, a team of hundreds of scientists has identified 50 drugs that may be effective treatments for people infected with the coronavirus. Continue reading

Posted in MS Treatment | Comments Off on Coronavirus Treatment: Hundreds of Scientists Scramble to Find One – The New York Times

Gilenya Linked to Slightly Increased Cancer Risk in MS, Swedish… – Multiple Sclerosis News Today

Posted: Published on March 20th, 2020

The risk of invasive cancer may be slightly higher in multiple sclerosis (MS) patients treated with Gilenya(fingolimod) compared with those treated with rituximab, and with people from the general population, a Swedish study suggests. The study, Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients, was published in the journal Annals of Neurology. Disease-modifying therapies (DMTs) have revolutionized how MS disease is managed. Continue reading

Posted in MS Treatment | Comments Off on Gilenya Linked to Slightly Increased Cancer Risk in MS, Swedish… – Multiple Sclerosis News Today

Coronavirus Tests Are Now Free, but Treatment Could Still Cost You – The New York Times

Posted: Published on March 20th, 2020

Government programs like Medicare and Medicaid are also covering the test, which isnt that expensive Medicare is paying anywhere from $36 to $51 for the actual test. People without insurance, or those enrolled in so-called junk plans that dont meet the standards for insurance under the Affordable Care Act, should also be able to get tested at no cost, said Karen Pollitz, a senior fellow at the Kaiser Family Foundation, which recently released an issue brief on private insurance coverage of coronavirus. But could I still end up with bills to pay? Continue reading

Posted in MS Treatment | Comments Off on Coronavirus Tests Are Now Free, but Treatment Could Still Cost You – The New York Times

Page 955«..1020..954955956957..960970..»